Lundbeck: Myriad Deal is a High Risk High Reward Strategy - RedOrbit by Alzheimers treatment

Wed, 28 May 2008 01:35:53 -0400

Lundbeck: Myriad Deal is a High Risk High Reward Strategy - RedOrbit

by Alzheimers treatment @ Wed, 28 May 2008 01:35:53 -0400

Lundbeck: Myriad Deal is a High Risk High Reward Strategy
RedOrbit, TX -May 22, 2008
Lundbeck has acquired the European commercialization rights to Myriad's new Alzheimer's treatment, Flurizan. However, late stage failures are common in the ...